A survey of current practice for antibody-mediated rejection in heart transplantation

American Journal of Transplantation

Volumn 13, Issue 4, 2013, Pages 1069-1074

  Chih, S ^a   Tinckam, K J ^b   Ross, H J ^c  

^a ROYAL PERTH HOSPITAL   (Australia)

^b Laboratory Medicine Program   (Australia)

^c TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Allograft dysfunction; antibody mediated rejection; donor specific antibody; heart transplantation; survey

Indexed keywords

IMMUNOGLOBULIN; RITUXIMAB; STEROID; THYMOCYTE ANTIBODY;

ANTIBODY MEDIATED REJECTION; CARDIAC GRAFT REJECTION; CLINICAL PRACTICE; DISEASE SEVERITY; EUROPE; HEALTH SURVEY; HEART EJECTION FRACTION; HEART TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL SOCIETY; NORTH AMERICA; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; STEROID THERAPY;

ALGORITHMS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTILYMPHOCYTE SERUM; COMPLEMENT ACTIVATION; EUROPE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; INTERNET; NORTH AMERICA; QUESTIONNAIRES; STEROIDS; TREATMENT OUTCOME;

EID: 84875723243     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12162     Document Type: Review

References (17)

1. Nair N, Ball T, Uber PA, Mehra MR,. Current and future challenges in therapy for antibody-mediated rejection. J Heart Lung Transplant 2011; 30: 612-617.
2. Berry GJ, Angelini A, Burke MM, et al. The ISHLT working formulation for pathologic diagnosis of antibody-mediated rejection in heart transplantation: Evolution and current status (2005-2011). J Heart Lung Transplant 2011; 30: 601-611.
3. Kobashigawa J, Crespo-Leiro MG, Ensminger SM, et al. Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 2011; 30: 252-269.
4. Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005; 24: 1710-1720. (Pubitemid 41641841)
5. Wu GW, Kobashigawa JA, Fishbein MC, et al. Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes. J Heart Lung Transplant 2009; 28: 417-422.
6. Kfoury AG, Hammond MEH, Snow GL, et al. Cardiovascular mortality among heart transplant recipients with asymptomatic antibody-mediated or stable mixed cellular and antibody-mediated rejection. J Heart Lung Transplant 2009; 28: 781-784.
7. Kfoury AG, Snow GL, Budge D, et al. A longitudinal study of the course of asymptomatic antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 2012; 31: 46-51.
8. Smith JD, Banner NR, Hamour IM, et al. De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival. Am J Transplant 2011; 11: 312-319.
9. Ho EK, Vlad G, Vasilescu ER, et al. Pre- and posttransplantation allosensitization in heart allograft recipients: Major impact of de novo alloantibody production on allograft survival. Human Immunol 2011; 72: 5-10.
10. Tambur AR, Pamboukian SV, Costanzo M-R, et al. The presence of HLA-directed antibodies after heart transplantation is associated with poor allograft outcome. Transplantation 2005; 80: 1019-1025. (Pubitemid 41611922)
11. Batal I, Zeevi A, Lunz JG, et al. Antihuman leukocyte antigen-specific antibody strength determined by complement-dependent or solid-phase assays can predict positive donor-specific crossmatches. Arch Pathol Lab Med 2010; 134: 1534-1540.
12. Chin C, Chen G, Sequeria F, et al. Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. J Heart Lung Transplant 2011; 30: 158-163.
13. Nath DS, Ilias Basha H, Tiriveedhi V, et al. Characterization of immune responses to cardiac self-antigens myosin and vimentin in human cardiac allograft recipients with antibody-mediated rejection and cardiac allograft vasculopathy. J Heart Lung Transplant 2010; 29: 1277-1285.
14. Nath DS, Tiriveedhi V, Basha HI, et al. A role for antibodies to human leukocyte antigens, collagen-V, and K-alpha1-Tubulin in antibody-mediated rejection and cardiac allograft vasculopathy. Transplantation 2011; 91: 1036-1043.
15. Grauhan O, Knosalla C, Ewert R, et al. Plasmapheresis and cyclophosphamide in the treatment of humoral rejection after heart transplantation. J Heart Lung Transplant 2001; 20: 316-321. (Pubitemid 32194632)
16. Jordan SC, Quartel AW, Czer LSC, et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control a humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 1998; 66: 800-805.
17. Kaczmarek I, Deutsch M-A, Sadoni S, et al. Successful management of antibody-mediated cardiac allograft rejection with combined immunoadsorption and anti-CD20 monoclonal antibody treatment: Case report and literature Review. J Heart Lung Transplant 2007; 26: 511-515. (Pubitemid 46602000)